Cisplatin의 난소암 세포 증식 억제에 관한 신호 전달 기전
Cisplatin Suppresses Proliferation of Ovarian Cancer Cells through Inhibition Akt and Modulation MAPK Pathways
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Cisplatin (CDDP)은 난소암 치료에 사용되는 화학 요법제로 암세포에 따라 그리고 치료 용량에 따라 다중 신호경로를 활성화하여 세포 반응을 다르게 일으킬 수 있다. Cisplatin이 세포에 작용하는 신호전달 기전은 분명하지 않아 더 많은 연구가 필요해 보인다. 이에 본 연구는 cisplatin을 난소암 세포(SKOV3) 에 처리하여 세포사멸 유도 과정에서 나타나는 신호 단백질의역할을 밝히고자 하였다. 결과는 cisplatin으로 처리한 난소암세포에서 TUNEL assay와 유세포 분석을 통해 대조군과 비교하여 세포 사멸수가 증가하였다. 세포 사멸 단계에서 나타나는PARP 및 caspase-3 활성도 증가하였다. 그러나 Bcl-2의 발현은 감소하였다. 신호 전달 경로에서 나타나는 단백질의 발현은ERK1/2의 활성은 시간 의존적으로 감소하였으나 Akt 활성은24시간에 감소하다 48시간에서의 활성은 일정하였다. p38과p-JUN의 활성은 24시간에 증가하는 것으로 나타났으나 48시간 에서 p38의 활성은 감소하였으며 p-JUN의 활성은 일정하였다. 이상의 결과들을 토대로 결론은 cisplatin이 SKOV3 세포에서 Akt 활성을 감소하여 세포 증식을 억제하고 MAPK의p38 발현을 조절하여 세포사멸을 유도하는 것으로 판단된다. 향후, 암치료 전략에 도움이 되는 cisplatin을 포함한 백금기반화학요법제의 신호전달 기전을 밝히기 위한 더 많은 연구가 필요할 것으로 생각된다. 본 실험을 통해 제시한 결과는 MAPK 신호 경로를 타겟으로 하는 암 치료 전략에 유용하게 사용 될 수 있기를 기대한다.
Abstract
Cisplatin (CDDP) is a chemotherapy agent used for patients with ovarian cancers. CDDP activates multiple signaling pathways, which causes various cellular reactions according to the type of cancer cells. Therefore, it is difficult to clearly conclude its signaling pathways. The purpose of this study is to determine the role of the signal protein of Akt/ERK1/2 and MAPK by CDDP-induced apoptosis in ovarian cancer cells (SKOV3). As a result, the number of apoptosis increased according to the TUNEL assay, and flow cytometric analysis confirmed that the percentage of sub-G1 early apoptosis was 8.73% higher than the control. The PARP and caspase-3 activity that appeared in the process of apoptosis was increased and the Bcl-2 expression was decreased. It was verified that the Akt and ERK1/2 activity was decreased, and p38 and JNK activity increased in a time dependent fashion. In conclusion, these results demonstrate that cisplatin inhibits the proliferation of ovarian cancer cells by inhibiting Akt activity and induces apoptosis by modulating the MAPK signaling pathway. However, a decrease in the ERK1/2 activity by CDDP was the opposite result to the result shown from the HeLa cells. For this reason, further research on signaling pathways is necessary. These results are expected to be useful for ovarian cancer treatment strategies targeting the MAPK pathway.
참고문헌 (35)
- Kathleen R. Cho, "Ovarian Cancer", Annual Review of Pathology: Mechanisms of Disease, 4(1), pp.287~313 (2009), Annual Reviews[DOI]
- Swisher EM, "Molecular scores to predict ovarian cancer outcomes : a worthy goal, but not ready for prime time", J Natl Cancer Inst, 104, pp.642~645 (2012)[DOI]
- Rebecca L. Siegel, "Cancer statistics, 2018", CA: A Cancer Journal for Clinicians, 68(1), pp.7~30 (2018), Wiley[DOI]
- Michael Frezza, "Novel Metals and Metal Complexes as Platforms for Cancer Therapy", Current Pharmaceutical Design, 16(16), pp.1813~1825 (2010), Bentham Science Publishers Ltd.[DOI]
- Di Chen, "Metal Complexes, their Cellular Targets and Potential for Cancer Therapy", Current Pharmaceutical Design, 15(7), pp.777~791 (2009), Bentham Science Publishers Ltd.[DOI]
- P. Golstein, "Controlling Cell Death", Science, 275(5303), pp.1081~1082 (1997), American Association for the Advancement of Science (AAAS)[DOI]
- Zeng Qiang Yuan, "Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase", Akt pathway in human ovarian cancer, 2000, pp.19(19), 2324~2330[DOI]
- T Lasky, "P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers.", Environmental Health Perspectives, 104(12), pp.1324~1331 (1996), Environmental Health Perspectives[DOI]
- George Kulik, "Akt-Dependent and -Independent Survival Signaling Pathways Utilized by Insulin-Like Growth Factor I", Molecular and Cellular Biology, 18(11), pp.6711~6718 (1998), American Society for Microbiology[DOI]
- Vuk Stambolic, "Negative Regulation of PKB", Akt-Dependent Cell Survival by the Tumor Suppressor PTEN, 1998, pp.95(1), 29~39[DOI]
- Jianguo Gu, "Tumor Suppressor PTEN Inhibits Integrin- and Growth Factor–mediated Mitogen-activated Protein (MAP) Kinase Signaling Pathways", Journal of Cell Biology, 143(5), pp.1375~1383 (1998), Rockefeller University Press[DOI]
- Y Tony Ip, "Signal transduction by the c-Jun N-terminal kinase (JNK) — from inflammation to development", Current Opinion in Cell Biology, 10(2), pp.205~219 (1998), Elsevier BV[DOI]
- MICHAEL KARIN, "Mitogen-Activated Protein Kinase Cascades as Regulators of Stress Responses", Annals of the New York Academy of Sciences, 851(1 STRESS OF LIF), pp.139~146 (1998), Wiley[DOI]
- Xiantao Wang, "Requirement for ERK Activation in Cisplatin-induced Apoptosis", Journal of Biological Chemistry, 275(50), pp.39435~39443 (2000), Elsevier BV[DOI]
- Maggie K.S. Tang, "c-Met Overexpression Contributes to the Acquired Apoptotic Resistance of Nonadherent Ovarian Cancer Cells through a Cross Talk Mediated by Phosphatidylinositol 3-Kinase and Extracellular Signal-Regulated Kinase 1", 2, 2010, pp.12(2), 128~IN5[DOI]
- Gang Chen, "Sevoflurane Induces Endoplasmic Reticulum Stress Mediated Apoptosis in Hippocampal Neurons of Aging Rats", PLoS ONE, 8(2), pp.e57870~ (2013), Public Library of Science (PLoS)[DOI]
- Guy S Salvesen, "Caspases: Intracellular Signaling by Proteolysis", Cell, 91(4), pp.443~446 (1997), Elsevier BV[DOI]
- S Fulda, "Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy", Oncogene, 25(34), pp.4798~4811 (2006), Springer Science and Business Media LLC[DOI]
- Guy S Salvesen, "Caspase activation – stepping on the gas or releasing the brakes? Lessons from humans and flies", Oncogene, 23(16), pp.2774~2784 (2004), Springer Science and Business Media LLC[DOI]
- Susan Elmore, "Apoptosis: A Review of Programmed Cell Death", Toxicologic Pathology, 35(4), pp.495~516 (2007), SAGE Publications[DOI]
- J.John Cohen, "Apoptosis", Immunology Today, 14(3), pp.126~130 (1993), Elsevier BV[DOI]
- Kaufmann SH, "Specific proteolytic cleavage of poly (ADP-ribose) polymerase:an early marker of chemotherapy-induced apoptosis", Cancer Res, 53, pp.3976~3985 (1993)
- , a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway, "British Journal of Pharmacology", 2008, 34~49, pp.Wiley, https:
- Stephen J. Ralph, "Cancer chemoprevention and mitochondria:targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics", redox state, 2009, pp.53(1), 49~67[DOI]
- Wei Qian, "Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death", American Journal of Physiology-Cell Physiology, 289(6), pp.C1466~C1475 (2005), American Physiological Society[DOI]
- Zahid H Siddik, "Cisplatin: mode of cytotoxic action and molecular basis of resistance", Oncogene, 22(47), pp.7265~7279 (2003), Springer Science and Business Media LLC[DOI]
- Seon-Joo Park, "The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells", British Journal of Pharmacology, 146(4), pp.506~513 (2005), Wiley[DOI]
- Erwin F. Wagner, "Signal integration by JNK and p38 MAPK pathways in cancer development", Nature Reviews Cancer, 9(8), pp.537~549 (2009), Springer Science and Business Media LLC[DOI]
- Bulavin DV, "p38 MAP kinase’s emerging role as a tumor suppressor", Adv Cancer Res, 92, pp.95~118 (2004)[DOI]
- Lufen Chang, "Mammalian MAP kinase signalling cascades", Nature, 410(6824), pp.37~40 (2001), Springer Science and Business Media LLC[DOI]
- G. L. Johnson, "Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases", Science, 298(5600), pp.1911~1912 (2002), American Association for the Advancement of Science (AAAS)[DOI]
- Derek P. Brazil, "Ten years of protein kinase B signalling: a hard Akt to follow", Trends in Biochemical Sciences, 26(11), pp.657~664 (2001), Elsevier BV[DOI]
- 권혁우, "PI3K, Akt, p38을 포함한 인산화단백질에 대한 Cordycepin의 억제효과", 대한임상검사과학회지, 49(2), pp.99~107 (2017), 대한임상검사과학회[DOI]
- Iman W. Achkar, "Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway", Journal of Translational Medicine, 16(1), pp.96~ (2018), Springer Science and Business Media LLC[DOI]
- Elisabeth Smolle, "Targeting Signaling Pathways in Epithelial Ovarian Cancer", International Journal of Molecular Sciences, 14(5), pp.9536~9555 (2013), MDPI AG[DOI]